Imagine a bandage that acts like a tiny laboratory on your skin. Instead of peeling off a dressing to check a wound, these special fibers sense signs of infection automatically. It's like having a 24/7 security guard for your healing process, alerting doctors before a problem becomes serious.
Chronic wounds affect 2% of the world population, creating a massive burden on healthcare costs. Currently, there are no reliable smart bandages on the market for continuous, early detection of complications.
A platform for wearable biosensors using electrospun hollow fibers and engineered enzymes for radial bio-signaling.
If you are a manufacturer dealing with the lack of smart bandages in the real market — this project developed electrospun neofibers that can be integrated into existing roll-to-roll processes. This allows you to upgrade standard dressings into active biosensors.
If you are a biotech company dealing with unstable biosensor signals — this project developed a new family of engineered biocatalysts, including resurrected enzymes. This ensures a more sensitive and reliable signal for health monitoring.
If you are a clinic dealing with the high cost of treating the 2% of the global population with chronic wounds — this project developed wearable biosensors that reduce unnecessary dressing changes. This optimizes resource use and lowers hospital visit frequency.
Based on available project data, specific pricing is not mentioned, but the goal is to reduce the substantial healthcare costs associated with chronic wound management.
Yes, the sensors are designed to be integrable into existing standard manufacturing processes such as suturing, embroidery, and roll-to-roll production.
Based on available project data, the project focuses on developing new families of detection biocatalysts and electrochemical materials, but specific patent or licensing terms are not listed.
It replaces traditional dressings with wearable biosensors that provide continuous monitoring, reducing the need for manual dressing changes and frequent hospital visits.
The project is active from November 1, 2023, to October 31, 2027.
The consortium consists of 4 partners across 3 countries (DE, ES, FR). It features a balanced mix of 1 SME (the coordinator), 1 university, and 2 research organizations, resulting in a 25% industry ratio. This structure suggests a strong focus on fundamental research and enzyme engineering with a clear path toward SME-led commercialization.
Contact EVOENZYME SL in Spain
Contact us to explore licensing opportunities for these engineered biocatalysts.
